BioSpaceOriginal article
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
Phase 3negativeCamlipixantNegative
AI Analysis
Summary
GSK has discontinued its camlipixant cough program, which was acquired as part of its $2 billion purchase of Bellus Health in April 2023, following a Phase 3 trial failure. The company determined the drug is unlikely to provide meaningful patient benefit.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 failure; GSK determined the drug is unlikely to transform patient care and culled the program
Importance:7/10
Sentiment:
-0.90
Phase_3_failureProgram_discontinuationAcquisition_impactCough_indication
Related Companies
Read the original article
Published by BioSpace on July 17, 2026 12:48 PM